ADCT earnings date and last-quarter result: last quarter miss, P/E -1.18. Updated 2026-07-23.
ADC Therapeutics (ADCT) Research Hub
ADC Therapeutics (ADCT) trades on NYSE, CH in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 1.51 USD (+4.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.18, market cap 0.15B. This hub links to the full technical, earnings and options research available for ADCT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, CH |
| Last close | 1.51 USD (+4.86%) |
| 52-week range | 0.939 USD – 1.87 USD |
| Trend regime | Range |
| 14-day RSI | 57.5 (Bullish) |
| Trailing P/E | -1.18 |
| Market cap | 0.15B |
| Dividend yield | 0.00% |
Available research for ADCT
Covered Call on ADCT: how it works, illustrative setup around the real 1.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ADCT: how it works, illustrative setup around the real 1.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ADCT: how it works, illustrative setup around the real 1.51 USD price, max profit/loss, breakeven and when to use it. Educational.
ADCT technical analysis: range, last 1.51 USD, RSI 57.5, 52w range 0.939 USD–1.87 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ADCT in?
ADC Therapeutics (ADCT) is classified under Healthcare (Biotechnology), listed on NYSE, CH.
Is ADCT in an uptrend or downtrend?
As of 2026-10-26, ADCT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ADCT's trailing P/E ratio?
ADCT's trailing P/E is -1.18, with a market cap of 0.15B. See the earnings research page for full valuation detail.